HK1095036A1 - Virus therapeutic drug - Google Patents

Virus therapeutic drug

Info

Publication number
HK1095036A1
HK1095036A1 HK07102519.1A HK07102519A HK1095036A1 HK 1095036 A1 HK1095036 A1 HK 1095036A1 HK 07102519 A HK07102519 A HK 07102519A HK 1095036 A1 HK1095036 A1 HK 1095036A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic drug
virus therapeutic
virus
drug
therapeutic
Prior art date
Application number
HK07102519.1A
Other languages
English (en)
Inventor
Masahiro Aoki
Hideyuki Kato
Masayuki Sudoh
Takuo Tsukuda
Miyako Masubuchi
Kenichi Kawasaki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of HK1095036A1 publication Critical patent/HK1095036A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK07102519.1A 2003-02-12 2007-03-07 Virus therapeutic drug HK1095036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003034056 2003-02-12
JP2003272420 2003-07-09
PCT/JP2004/001498 WO2004071503A1 (ja) 2003-02-12 2004-02-12 ウイルス治療薬

Publications (1)

Publication Number Publication Date
HK1095036A1 true HK1095036A1 (en) 2007-04-20

Family

ID=32871168

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102519.1A HK1095036A1 (en) 2003-02-12 2007-03-07 Virus therapeutic drug

Country Status (16)

Country Link
US (2) US7776918B2 (es)
EP (1) EP1593378B1 (es)
JP (1) JP3921227B2 (es)
KR (1) KR101071014B1 (es)
AU (1) AU2004211850B2 (es)
BR (1) BRPI0407140A (es)
CA (1) CA2515370C (es)
HK (1) HK1095036A1 (es)
IL (1) IL169551A (es)
MX (1) MXPA05008507A (es)
MY (1) MY141506A (es)
NO (1) NO20053348L (es)
NZ (1) NZ542250A (es)
RU (1) RU2350600C2 (es)
TW (1) TWI335219B (es)
WO (1) WO2004071503A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1819990B (zh) 2003-07-09 2010-04-21 中外制药株式会社 具有抗hcv作用的化合物及其制法
JP2006077004A (ja) * 2004-08-11 2006-03-23 Chugai Pharmaceut Co Ltd 抗ｈｃｖ作用を有する化合物およびそれを含む医薬組成物
JP4849622B2 (ja) * 2004-08-11 2012-01-11 中外製薬株式会社 Ｈｃｖ感染症を治療または予防するための薬剤
US7897783B2 (en) * 2005-02-17 2011-03-01 Chugai Seiyaku Kabushiki Kaisha Intermediate compound for synthesis of viridiofungin a derivative
US20110098477A1 (en) * 2005-06-28 2011-04-28 Chugai Seiyaku Kabushiki Kaisha Method Of Producing Compound Having Anti-Hcv Activity
KR20090021163A (ko) 2006-05-16 2009-02-27 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
EP2610343A3 (en) 2008-11-26 2013-09-25 Chugai Seiyaku Kabushiki Kaisha Method for designing siRNA and oligoribonucleotides inhibiting HCV
JP2013121935A (ja) 2011-12-12 2013-06-20 Institute Of Microbial Chemistry 化合物、及び不斉合成反応
EP2886530A4 (en) 2012-08-17 2016-01-27 Chugai Pharmaceutical Co Ltd ORAL ADMINISTRATIVE VIRIDIDEIN DERIVATIVE WITH ANTI-HCV ACTIVITY
JP5933867B1 (ja) * 2016-03-28 2016-06-15 公益財団法人微生物化学研究会 化合物、及び不斉合成反応
CN114105855B (zh) * 2020-08-31 2024-03-15 中国科学院大连化学物理研究所 一种在吲哚c2位引入异戊烯基的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526936A3 (en) * 1991-08-02 1993-05-05 Merck & Co. Inc. Cholesterol-lowering agents
US5364948A (en) * 1991-08-02 1994-11-15 Merck & Co., Inc. Biologically active compounds isolated from aerobic fermentation of Trichoderma viride
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
EP1002793B1 (en) * 1997-06-09 2003-09-24 Takara Bio Inc. Physiologically active substances tkr2449, process for producing the same, and microorganism

Also Published As

Publication number Publication date
AU2004211850B2 (en) 2009-06-04
TWI335219B (en) 2011-01-01
JP3921227B2 (ja) 2007-05-30
RU2005128297A (ru) 2006-02-27
CA2515370C (en) 2012-01-17
TW200501940A (en) 2005-01-16
KR20050098929A (ko) 2005-10-12
MY141506A (en) 2010-05-14
NZ542250A (en) 2008-12-24
US20100274026A1 (en) 2010-10-28
RU2350600C2 (ru) 2009-03-27
MXPA05008507A (es) 2005-10-20
BRPI0407140A (pt) 2006-02-07
AU2004211850A1 (en) 2004-08-26
NO20053348L (no) 2005-09-12
KR101071014B1 (ko) 2011-10-06
US7776918B2 (en) 2010-08-17
US20060217434A1 (en) 2006-09-28
AU2004211850A2 (en) 2009-02-12
WO2004071503A1 (ja) 2004-08-26
CA2515370A1 (en) 2004-08-26
IL169551A (en) 2011-10-31
NO20053348D0 (no) 2005-07-11
EP1593378A1 (en) 2005-11-09
JPWO2004071503A1 (ja) 2006-06-01
EP1593378B1 (en) 2013-09-25
EP1593378A4 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
HK1095036A1 (en) Virus therapeutic drug
IL174690A0 (en) Enhanced drug delivery
EP1691718A4 (en) THERAPEUTIC MICROTEILS
GB0307918D0 (en) Therapeutic use
EP1581188A4 (en) DOSAGE FORM WITH PHARMACEUTICAL SAFETY
ZA200410229B (en) Administration of therapeutic viruses
GB0316912D0 (en) Therapeutic treatment
GB0320806D0 (en) Therapeutic treatment
EP1693079A4 (en) MEDICAL SYRINGE
GB0329275D0 (en) Therapeutic treatment
GB2401043B (en) Drug
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
EP1485077A4 (en) DRUGS COMBINATION THERAPY
GB0327493D0 (en) Treatment medicament
PL1618130T3 (pl) Szczepionka terapeutyczna przeciw nowotworom
EP1624073A4 (en) DRUG
GB0307333D0 (en) Therapeutic agent
GB0327912D0 (en) Medicament
GB0301842D0 (en) Medicament
GB0327913D0 (en) Medicament
GB0325021D0 (en) Therapeutic combinations
GB0329141D0 (en) Drug delivery
GB0311084D0 (en) Drug delivery
GB0308469D0 (en) Pharmaceutical combination

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130212